John R. Lydeard

Biogen (United States) — United States

Medicine · Health Sciences

14h-index2.9kcitations30works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(9), CRISPR and Genetic Engineering(8), Advanced biosensing and bioanalysis techniques(7), DNA Repair Mechanisms(5), Ubiquitin and proteasome pathways(5)

Publications30 total

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT
Blood·2026
A Human Genetics Framework for De-risking Gene Editing Targets for Hematopoietic Cell and Gene Therapy
2025Open Access
Cutting Through the Artifacts: Dissecting gRNA Impurities with FUSS-seq
2025Open Access
Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML Therapy
2025Open Access
A resource and computational approach for quantifying gene editing allelism at single-cell resolution
2025Open Access
Multimodal Atlas of Paired Diagnosis and Relapse AML Reveals Surface Antigens for Multi-Specific Immunotherapy
Blood·2024Open Access
1092 Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to treat AML
Regular and Young Investigator Award Abstracts·2024Open Access
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
Molecular Therapy — Methods & Clinical Development·2023· 3 citedOpen Access
Multimodal Atlas of Paired Diagnosis and Relapse AML Samples Enables Novel Therapeutic Targeting of Surface Antigens
Blood·2023· 1 citedOpen Access
CD33-Deleted Hematopoietic Cells (Trem-Cel) Are Protected from CD33xCD3 Bispecific Antibody Treatment and Produce Significantly Reduced Levels of Inflammatory Cytokines in Preclinical Studies
Blood·2023
260 Novel CLL-1-directed CAR-T cells mediate potent antigen-specific cytolytic activity in mouse models of acute myeloid leukemia
Regular and Young Investigator Award Abstracts·2023Open Access
Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity
Molecular Therapy — Methods & Clinical Development·2023· 16 citedOpen Access
MKRN3 inhibits puberty onset via interaction with IGF2BP1 and regulation of hypothalamic plasticity
JCI Insight·2023· 25 citedOpen Access
Efficient Multiplex Gene Editing of CD33 and CLL-1 in Human Hematopoietic Stem Cells Enables the Potential of Next-Generation Transplants for AML Treatment
Blood·2022
Longitudinal Multimodal Atlas of AML Surface Antigens Enables Adaptive and Combinatorial Targeting
Blood·2022
Multiplex Engineering of Human CD34+ HSPCs Enables Dual Gene Knock-out While Maintaining High Engraftment Potential and Safety
Blood·2021
Knock out of CD123 or CLL-1 By CRISPR-Cas9 Editing from Human Hematopoietic Stem Cell Transplants Provide New Possibilities for Increasing Therapeutic Index and Safety for AML Treatment
Blood·2021· 1 cited
Erratum: Corrigendum: Systematic proteomics of the VCP–UBXD adaptor network identifies a role for UBXN10 in regulating ciliogenesis
Nature Cell Biology·2016· 74 citedOpen Access
Systematic proteomics of the VCP–UBXD adaptor network identifies a role for UBXN10 in regulating ciliogenesis
Nature Cell Biology·2015· 98 citedOpen Access
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Nature·2014· 1.0k citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Tirtha Chakraborty(14), Julia Etchin(12), Yonina Keschner(11), Amanda L. Halfond(10), J. Wade Harper(8), Huanying Gary Ge(8), Michelle I. Lin(7), Gabriella Angelini(6), Julian Scherer(6), Guy Mundelboim(6), Jessica Lisle(5), Matthew Ung(5), Mariana Silva(5), James E. Haber(4), Juliana Xavier-Ferrucio(4), Hannah Mager(4), Jianxin Hu(4), Julia DiFazio(4), Alyssa Pyclik(4), Suvi Jain(3)